Compare

Keros Therapeutics/$KROS

1D1W1M3M6MYTD1Y5YMAX

About Keros Therapeutics

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
$KROS
Sector
Health
Primary listing
NASDAQ
Employees
87

KROS Metrics

BasicAdvanced
$224M
-
-$2.86
1.19
-

What the Analysts think about KROS

Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
Analyst projections of the future price of Keros Therapeutics stock.

KROS Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

KROS Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.